Frataxin mRNA Isoforms in FRDA Patients and Normal Subjects: Effect of Tocotrienol Supplementation
Figure 2
(a) Semiquantitative PCR analysis of frataxin isoforms in a control subject. Equal amount of a control subject cDNA was used for FXN-1, FXN-2, and FXN-3 semiquantitative PCR analysis. PCR products were run in an agarose gel electrophoresis (2.5%). M: DNA ladder; NC: negative control. (b) qRT-PCR expression of frataxin isoforms. Frataxin isoform mRNA expression was analyzed by qRT-PCR in five healthy subjects (Ctr) and in five FRDA patients before (white columns) and after (grey columns) two-month tocotrienol supplementation. Data were normalized for two housekeeping genes, beta-actin and GAPDH; for each gene target, the normalized expression value of one control subject arbitrarily chosen was set to 1, and all other gene expression data were reported to that sample. Data are expressed as mean of technical triplicates ± SD and analyzed by ANOVA. Following tocotrienol supplementation, FXN-3 mRNA increased 3.49-fold in FRDA patients ().
(a) Semiquantitative PCR analysis of frataxin isoforms in a control subject
